ARCH — Arch Biopartners Income Statement
0.000.00%
Last trade - 00:00- CA$54.22m
- CA$57.05m
- CA$0.28m
Annual income statement for Arch Biopartners, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.89 | 0.965 | 1.98 | 2.12 | 0.276 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Operating Interest Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.05 | 2.35 | 5.34 | 6.07 | 1.78 |
| Operating Profit | -1.16 | -1.39 | -3.36 | -3.95 | -1.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.17 | -1.41 | -3.33 | -3.92 | -1.55 |
| Net Income After Taxes | -1.17 | -1.41 | -3.33 | -3.92 | -1.55 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.17 | -1.41 | -3.33 | -3.92 | -1.55 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.17 | -1.41 | -3.33 | -3.92 | -1.55 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.019 | -0.023 | -0.053 | -0.062 | -0.024 |